{"id":"W4389220730","doi":"10.1182/blood-2023-182019","title":"Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Refractory (planetary science); Oncology; Cohort; Salvage therapy; Neutropenia; Chemotherapy regimen; Chemotherapy; Gastroenterology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003325323,0.0005747081,0.001693669,0.0004990693,0.0001816,0.001073343,0.0005868429,0.0006433483,0.001029878],"category_scores_gemma":[0.002147988,0.0003662808,0.001954085,0.0006240713,0.0003037007,0.0007980753,0.0002671039,0.001149675,0.0001791314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008877961,"about_ca_system_score_gemma":0.0008701025,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000875852,"about_ca_topic_score_gemma":0.003480539,"domain_scores_codex":[0.9991115,0.0004246274,0.00008930372,0.0001417216,0.0001467487,0.00008613493],"domain_scores_gemma":[0.9983177,0.0004724048,0.0006793241,0.0001054291,0.000171015,0.0002542058],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3148247,0.004463117,0.1439904,0.004896747,0.02013233,0.000610446,0.0003590373,0.003159153,0.03875453,0.0003531855,0.008319018,0.4601374],"study_design_scores_gemma":[0.2701531,0.1466715,0.5012673,0.00107801,0.03016549,0.003191386,0.0002533236,0.003807215,0.006131484,0.0007700128,0.03633106,0.0001800552],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9336061,0.05872137,0.0007494016,0.0009750387,0.0001635785,0.0009400583,0.002318945,0.00009941994,0.002425949],"genre_scores_gemma":[0.9790561,0.01360022,0.001323499,0.001419317,0.0002308715,0.0005051098,0.003319678,0.0000231838,0.0005220508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003325323,"threshold_uncertainty_score":0.01758623,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02052508830690283,"score_gpt":0.307566127537709,"score_spread":0.2870410392308061,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}